中华实验和临床病毒学杂志
中華實驗和臨床病毒學雜誌
중화실험화림상병독학잡지
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL VIROLOGY
2013年
3期
196-198
,共3页
派罗欣%肝炎,乙型,慢性%丙氨酸转氨酶
派囉訢%肝炎,乙型,慢性%丙氨痠轉氨酶
파라흔%간염,을형,만성%병안산전안매
Pegasys%Hepatitis B,chronic%Alanine transaminase
目的 了解派罗欣对ALT低水平但肝组织炎症活动度≥G2的慢性乙型肝炎患者的疗效.方法 随机选择52例ALT低水平(ALT ＜2×ULN)但肝组织炎症活动度≥G2的慢性乙型肝炎患者为观察组,55例ALT＞2 ×ULN的慢性乙型肝炎患者为对照组,分别接受派罗欣治疗48周,并对两组患者的疗效进行比较.计量资料采用t检验,计数资料采用x2检验.结果 观察组HBV DNA下降值(log10拷贝/ml)在治疗不同时期均低于对照组(均P＜0.05).治疗结束时观察组HBV DNA转阴率、HBeAg血清转换率及HBsAg转阴率分别为51.9％、48.8％和1.9％；对照组分别为67.3％、66.7％和7.3％；两组比较差异均有统计学意义(均P＜0.05).两组患者的ALT复常率分别为75％和76.4％ (P ＞0.05).结论 派罗欣对ALT低水平但肝组织炎症活动度≥G2的慢性乙型肝炎患者有一定疗效,但仍逊于ALT＞2×ULN者.
目的 瞭解派囉訢對ALT低水平但肝組織炎癥活動度≥G2的慢性乙型肝炎患者的療效.方法 隨機選擇52例ALT低水平(ALT ＜2×ULN)但肝組織炎癥活動度≥G2的慢性乙型肝炎患者為觀察組,55例ALT＞2 ×ULN的慢性乙型肝炎患者為對照組,分彆接受派囉訢治療48週,併對兩組患者的療效進行比較.計量資料採用t檢驗,計數資料採用x2檢驗.結果 觀察組HBV DNA下降值(log10拷貝/ml)在治療不同時期均低于對照組(均P＜0.05).治療結束時觀察組HBV DNA轉陰率、HBeAg血清轉換率及HBsAg轉陰率分彆為51.9％、48.8％和1.9％；對照組分彆為67.3％、66.7％和7.3％；兩組比較差異均有統計學意義(均P＜0.05).兩組患者的ALT複常率分彆為75％和76.4％ (P ＞0.05).結論 派囉訢對ALT低水平但肝組織炎癥活動度≥G2的慢性乙型肝炎患者有一定療效,但仍遜于ALT＞2×ULN者.
목적 료해파라흔대ALT저수평단간조직염증활동도≥G2적만성을형간염환자적료효.방법 수궤선택52례ALT저수평(ALT ＜2×ULN)단간조직염증활동도≥G2적만성을형간염환자위관찰조,55례ALT＞2 ×ULN적만성을형간염환자위대조조,분별접수파라흔치료48주,병대량조환자적료효진행비교.계량자료채용t검험,계수자료채용x2검험.결과 관찰조HBV DNA하강치(log10고패/ml)재치료불동시기균저우대조조(균P＜0.05).치료결속시관찰조HBV DNA전음솔、HBeAg혈청전환솔급HBsAg전음솔분별위51.9％、48.8％화1.9％；대조조분별위67.3％、66.7％화7.3％；량조비교차이균유통계학의의(균P＜0.05).량조환자적ALT복상솔분별위75％화76.4％ (P ＞0.05).결론 파라흔대ALT저수평단간조직염증활동도≥G2적만성을형간염환자유일정료효,단잉손우ALT＞2×ULN자.
Objective To observe the therapeutic effects of Pegasys (pegylated interferon α-2a)in chronic hepatitis B (CHB) patients with low-level alanine transarninase (ALT) ＜ 2 × upper limit of normal (ULN).Methods One hundred and seven CHB patients were randomized enrolled including 52 with ALT ＜ 2 × ULN and liver tissues inflammation activity≥ G2 as observational group and 55 with ALT ＞ 2 × ULN as control group.All the enrolled patients received pegasys treatment for 48 weeks and the responses between two groups were compared.Measurement data were analyzed using t test and numeration data were analyzed using chi square test.Results The reductions of HBV DNA in observational group at different time points were all less than control group (all P ＜ 0.05).At the end of treatment,the HBV DNA negative rate,HBeAg seroconversion rate and HBsAg loss rate in the observational group were 51.9％,48.8％ and 1.9％,respectively,which were all lower than control group (67.3％,66.7％ and 7.3％,respectivley) (all P ＜ 0.05).The ALT normalization rates of two groups were 75％ and 76.4％ (P ＞ 0.05).Conclusion Pegasys is efficient for CHB patients with ALT ＜ 2 × ULN and liver tissues inflammation activity ≥ G2,while it is still inferior to those with ALT ＞ 2 × ULN.
